Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation
- PMID: 28988211
- PMCID: PMC5831356
- DOI: 10.1136/heartjnl-2016-311002
Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation
Abstract
Objective: Limited data exist on the association between menopause and atrial fibrillation (AF). We sought to examine the relationship between menopausal age, postmenopausal hormone therapy (PHT) use and incident AF.
Methods: The Women's Health Study (WHS) enrolled 39 876 female health professionals between 1992 and 1995. We prospectively examined 30 034 women in WHS using Cox proportional-hazard models. Participants were free of cardiovascular disease and AF at baseline and had not undergone hysterectomy without bilateral oophorectomy prior to menopause. Incident AF was confirmed by medical record review.
Results: At baseline, median age was 53 years (IQR 49-60), median menopausal age was 50 years (IQR 46-52) and 14 415 (48.0%) had prior PHT use. Over a median follow-up of 20.5 years, 1350 AF events occurred. In multivariable analysis, relative hazards for AF were lower among women with younger age at menopause but did not differ significantly from women with the oldest menopausal age (<45: HR 0.82, 95% CI 0.67 to 1.02; 45-49: HR 0.90, 95% CI 0.74 to 1.08; 50-54: HR 0.89, 95% CI 0.75 to 1.06; >54 years: referent). Use of oestrogen-alone PHT, but not oestrogen and progesterone, was independently associated with AF risk (HR 1.22; 95% CI 1.02 to 1.45 vs HR 1.04; 95% CI 0.86 to 1.26). This relationship was not attenuated by intermediary cardiovascular events.
Conclusions: In this large prospective study, menopausal age was not significantly related to incident AF, while use of oestrogen monotherapy was associated with increased AF risk. Our findings suggest a pathophysiological link between unopposed oestrogen exposure and AF in women.
Clinical trial registration: NCT000000479; Post-results.
Trial registration: ClinicalTrials.gov NCT00000479.
Keywords: Atrial fibrillation; Epidemiology; Menopausal Age; Menopause; Post-menopausal Hormone Therapy; Women.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: None declared.
Figures
Comment in
-
Atrial fibrillation and menopause: something else to worry about, or not?Heart. 2017 Dec;103(24):1930-1931. doi: 10.1136/heartjnl-2017-311771. Epub 2017 Aug 5. Heart. 2017. PMID: 28780573 No abstract available.
Similar articles
-
Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials.Circ Arrhythm Electrophysiol. 2012 Dec;5(6):1108-16. doi: 10.1161/CIRCEP.112.972224. Epub 2012 Nov 20. Circ Arrhythm Electrophysiol. 2012. PMID: 23169946 Clinical Trial.
-
Age of natural menopause and atrial fibrillation: the Framingham Heart Study.Am Heart J. 2012 Apr;163(4):729-34. doi: 10.1016/j.ahj.2012.01.010. Epub 2012 Mar 29. Am Heart J. 2012. PMID: 22520541 Free PMC article.
-
Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation.JAMA Cardiol. 2016 Jul 1;1(4):389-96. doi: 10.1001/jamacardio.2016.0280. JAMA Cardiol. 2016. PMID: 27438314 Free PMC article.
-
Menopause and post-menopause.Baillieres Clin Endocrinol Metab. 1997 Jul;11(2):311-40. doi: 10.1016/s0950-351x(97)80317-5. Baillieres Clin Endocrinol Metab. 1997. PMID: 9403125 Review.
-
Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?Curr Vasc Pharmacol. 2019;17(6):564-572. doi: 10.2174/1570161116666180709095348. Curr Vasc Pharmacol. 2019. PMID: 29984659 Review.
Cited by
-
Breast Cancer and Atrial Fibrillation.J Clin Med. 2022 Mar 4;11(5):1417. doi: 10.3390/jcm11051417. J Clin Med. 2022. PMID: 35268508 Free PMC article. Review.
-
Seeking predictors for paroxysmal atrial fibrillation in stroke with an online clinical database.North Clin Istanb. 2019 Dec 5;7(4):378-385. doi: 10.14744/nci.2019.91668. eCollection 2020. North Clin Istanb. 2019. PMID: 33043264 Free PMC article.
-
Application of plasma metabolome for monitoring the effect of rivaroxaban in patients with nonvalvular atrial fibrillation.PeerJ. 2022 Aug 9;10:e13853. doi: 10.7717/peerj.13853. eCollection 2022. PeerJ. 2022. PMID: 35966924 Free PMC article.
-
Clinical Impact of Hormone Replacement Therapy on Atrial Fibrillation in Postmenopausal Women: A Nationwide Cohort Study.J Clin Med. 2021 Nov 24;10(23):5497. doi: 10.3390/jcm10235497. J Clin Med. 2021. PMID: 34884201 Free PMC article.
-
Differences in Epidemiology and Risk Factors for Atrial Fibrillation Between Women and Men.Front Cardiovasc Med. 2020 Jan 31;7:3. doi: 10.3389/fcvm.2020.00003. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 32118043 Free PMC article. Review.
References
-
- Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–5. - PubMed
-
- Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840–4. - PubMed
-
- Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155:469–73. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical